Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 37

Sort by

Sort Order Select

Journal Articles

The Influence of Cardiovascular Comorbidities in Adverse-Risk Acute Myeloid Leukemia

Alsten Jones, Angelica Johnson, Keri Maher

Blood (2024) 144 (Supplement 1): 5967.

https://doi.org/10.1182/blood-2024-206198

Published: 2024

Journal Articles

Selinexor-Driven Regulation of Proinflammatory Cytokines May Lead to Stabilization of Hematologic Parameters and Bone Marrow Function in Patients with Myelofibrosis: Case Study from the Phase 1 Sentry Trial

Haris Ali, Keri Maher, Ashwin Kishtagari, Sanjay R Mohan, Josef T. Prchal, Yi Chai, Christopher J. Walker, Trinayan Kashyap, Steve Kye, Srinivas K Tantravahi

Blood (2024) 144 (Supplement 1): 6676.

https://doi.org/10.1182/blood-2024-207778

Published: 2024

Journal Articles

Shifting Treatment Paradigms and Clinical Outcomes in TP53 Mutated Acute Myeloid Leukemia

Hyun Lee, Luke Kicklighter, Thuy Ho, George Avetian, Graeme F Murray, Natasha Dziarnowski, Ian M. Bouligny, Keri Maher

Blood (2024) 144 (Supplement 1): 7909.

https://doi.org/10.1182/blood-2024-206123

Published: 2024

Journal Articles

Older Age at Time of Allogeneic Stem Cell Transplant Is Associated with Inferior Outcomes in Patients with Acute Myeloid Leukemia

George Avetian, Thuy Ho, Graeme F Murray, Ian M. Bouligny, Keri Maher

Blood (2024) 144 (Supplement 1): 7389.

https://doi.org/10.1182/blood-2024-206144

Published: 2024

Journal Articles

Prognostic Impact of PTPN11 mutations in Acute Myeloid Leukemia

Thuy Ho, Luke Kicklighter, George Avetian, Graeme F Murray, Ian M. Bouligny, Hyun Lee, Natasha Dziarnowski, Keri Maher

Blood (2024) 144 (Supplement 1): 6120.

https://doi.org/10.1182/blood-2024-211478

Published: 2024

Journal Articles

Hypomethylating Agents and Venetoclax or Hypomethylating Agents Alone in Acute Myeloid Leukemia in Patients with Significant Comorbidities

Graeme F Murray, Ian M. Bouligny, Thuy Ho, Juhi F Gohr, Keri Maher

Blood (2024) 144 (Supplement 1): 6083.

https://doi.org/10.1182/blood-2024-193042

Published: 2024

Journal Articles

Comparison of Cytoreductive Therapies for Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: A Perspective on the Updated American Society for Apheresis Guidelines

George Avetian, Thuy Ho, Ian M. Bouligny, Hyun Lee, Keri Maher

Blood (2024) 144 (Supplement 1): 7637.

https://doi.org/10.1182/blood-2024-206090

Published: 2024

Journal Articles

A Phase I Dose Escalation and Expansion Trial of Lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in Relapsed/Refractory AML/MDS

Amir T. Fathi, Aleksandra Filipovic, Keri Maher, Dale G Schaar, Rabin Niroula, Joseph J. Maly, Deepa Jaykumar, Noah Merin, Jay Yang, Jorge R. Galvez Silva, Varun Gang, Taylor Meeks, Christopher Korth, Guenther Koehne

Blood (2024) 144 (Supplement 1): 1499.

https://doi.org/10.1182/blood-2024-209848

Published: 2024

Journal Articles

Recent Advancements in Acute Myeloid Leukemia Have Led to Incremental Improvement in Overall Survival

Thuy Ho, Graeme Murray, Juhi Gor, Ian Bouligny, Keri Maher

Blood (2023) 142 (Supplement 1): 5187.

https://doi.org/10.1182/blood-2023-183022

Published: 2023

Journal Articles

Toward a Measurable Residual Disease-Based Algorithm for Selection of Allogeneic Hematopoietic Stem Cell Transplant in Acute Myeloid Leukemia

Thuy Ho, Juhi Gor, Ian Bouligny, Graeme Murray, Keri Maher

Blood (2023) 142 (Supplement 1): 7090.

https://doi.org/10.1182/blood-2023-182190

Published: 2023

Journal Articles

Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

Srinivas K. Tantravahi, Ashwin Kishtagari, Keri Maher, Sanjay Mohan, Josef T. Prchal, Xulong Wang, Kamal Chamoun, Christopher J Walker, Pietro Taverna, Haris Ali

Blood (2023) 142 (Supplement 1): 622.

https://doi.org/10.1182/blood-2023-180844

Published: 2023

Journal Articles

Impact of Recent Advancements in Relapsed/Refractory Acute Myeloid Leukemia on Overall Survival in Clinical Practice

Thuy Ho, Juhi Gor, Graeme Murray, Ian Bouligny, Keri Maher

Blood (2023) 142 (Supplement 1): 1474.

https://doi.org/10.1182/blood-2023-185132

Published: 2023

Journal Articles

First-Line Venetoclax and a Hypomethylating Agent or Conventional Chemotherapy in Older Adults with IDH -Mutated AML

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher

Blood (2023) 142 (Supplement 1): 1488.

https://doi.org/10.1182/blood-2023-188400

Published: 2023

Journal Articles

Validation of the Charlson Comorbidity Index Model in Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher

Blood (2023) 142 (Supplement 1): 5093.

https://doi.org/10.1182/blood-2023-189322

Published: 2023

Journal Articles

Impact of COVID-19 Pandemic on Overall Survival in Acute Myeloid Leukemia: A Comprehensive Cancer Center Experience of 627 Patients

Juhi Gor, Ian Bouligny, Thuy Ho, Graeme Murray, Keri Maher

Blood (2023) 142 (Supplement 1): 7437.

https://doi.org/10.1182/blood-2023-190759

Published: 2023

Journal Articles

The Impact of Delayed Venetoclax Initiation on Overall Survival in Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher

Blood (2023) 142 (Supplement 1): 4233.

https://doi.org/10.1182/blood-2023-188249

Published: 2023

Journal Articles

A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034)

Keri Maher, Raajit K. Rampal, Prithviraj Bose, Nikolai A. Podoltsev, Claire N Harrison, Junshik Hong, Xulong Wang, Kamal Chamoun, John Mascarenhas

Blood (2023) 142 (Supplement 1): 3209.

https://doi.org/10.1182/blood-2023-180695

Published: 2023

Journal Articles

Phase 1b/2 Study of Escalating Doses of the NEDD8 Activating Enzyme Inhibitor Pevonedistat Administered in Combination with Standard Induction Therapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4279.

https://doi.org/10.1182/blood-2023-185481

Published: 2023

Journal Articles

Clinical Significance of Clonal Evolution: A Comparison of Relapsed Versus Refractory Acute Myeloid Leukemia

Graeme Murray, Ian Bouligny, Thuy Ho, Juhi Gor, Keri Maher

Blood (2023) 142 (Supplement 1): 4310.

https://doi.org/10.1182/blood-2023-185146

Published: 2023

Journal Articles

CPX-351 Versus FLAG-IDA with or without Venetoclax in Previously Untreated and Relapsed or Refractory Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher

Blood (2023) 142 (Supplement 1): 4269.

https://doi.org/10.1182/blood-2023-189184

Published: 2023

NARROW

The Influence of Cardiovascular Comorbidities in Adverse-Risk Acute Myeloid Leukemia

Selinexor-Driven Regulation of Proinflammatory Cytokines May Lead to Stabilization of Hematologic Parameters and Bone Marrow Function in Patients with Myelofibrosis: Case Study from the Phase 1 Sentry Trial

Shifting Treatment Paradigms and Clinical Outcomes in TP53 Mutated Acute Myeloid Leukemia

Older Age at Time of Allogeneic Stem Cell Transplant Is Associated with Inferior Outcomes in Patients with Acute Myeloid Leukemia

Prognostic Impact of PTPN11 mutations in Acute Myeloid Leukemia

Hypomethylating Agents and Venetoclax or Hypomethylating Agents Alone in Acute Myeloid Leukemia in Patients with Significant Comorbidities

Comparison of Cytoreductive Therapies for Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: A Perspective on the Updated American Society for Apheresis Guidelines

A Phase I Dose Escalation and Expansion Trial of Lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in Relapsed/Refractory AML/MDS

Recent Advancements in Acute Myeloid Leukemia Have Led to Incremental Improvement in Overall Survival

Toward a Measurable Residual Disease-Based Algorithm for Selection of Allogeneic Hematopoietic Stem Cell Transplant in Acute Myeloid Leukemia

Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

Impact of Recent Advancements in Relapsed/Refractory Acute Myeloid Leukemia on Overall Survival in Clinical Practice

First-Line Venetoclax and a Hypomethylating Agent or Conventional Chemotherapy in Older Adults with IDH -Mutated AML

Validation of the Charlson Comorbidity Index Model in Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax

Impact of COVID-19 Pandemic on Overall Survival in Acute Myeloid Leukemia: A Comprehensive Cancer Center Experience of 627 Patients

The Impact of Delayed Venetoclax Initiation on Overall Survival in Acute Myeloid Leukemia

A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034)

Phase 1b/2 Study of Escalating Doses of the NEDD8 Activating Enzyme Inhibitor Pevonedistat Administered in Combination with Standard Induction Therapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myeloid Leukemia

Clinical Significance of Clonal Evolution: A Comparison of Relapsed Versus Refractory Acute Myeloid Leukemia

CPX-351 Versus FLAG-IDA with or without Venetoclax in Previously Untreated and Relapsed or Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only